RxSight, Inc. (NASDAQ:RXST) Given Average Recommendation of "Reduce" by Brokerages
RxSight, Inc. (NASDAQ:RXST) has received a consensus "Reduce" recommendation from fifteen brokerages, with an average 12-month target price of $9.7778. Analysts have issued a mix of sell, hold, and buy ratings, and several have recently adjusted their price targets for the company. Institutional investors and hedge funds hold a significant portion of RxSight's stock.
RxSight (RXST) to Release Earnings on Wednesday
RxSight (NASDAQ: RXST) is scheduled to release its Q4 2025 earnings after market close on Wednesday, February 25, 2026, with analysts forecasting a loss of $0.25 per share and revenue around $32.6 million. The stock is currently trading below its 50-day and 200-day moving averages, and analysts have a mixed-to-negative sentiment with a consensus "Reduce" rating and a price target of $9.78. Institutional investors have recently increased their positions in the medical technology company.
Earnings Preview: RxSight, Inc. (RXST) Q4 Earnings Expected to Decline
RxSight, Inc. (RXST) is expected to report a year-over-year decline in Q4 2025 earnings and revenue, with analysts forecasting a quarterly loss of $0.23 per share and revenues of $32.6 million. Despite a negative Zacks Rank #4, the company's Earnings ESP of +52.86% suggests that recent analyst revisions are bullish on its prospects. Investors should consider the Earnings ESP and Zacks Rank, along with other factors, before the earnings release on February 25, 2026.
Understanding the Setup: (RXST) and Scalable Risk
This article analyzes Rxsight Inc. (NASDAQ: RXST) using AI models, indicating a near-term neutral sentiment but a pause in mid and long-term weakness. It highlights an exceptional 231.5:1 risk-reward setup targeting a 78.5% gain versus 0.3% risk. The analysis provides specific institutional trading strategies for various risk profiles, including position trading, momentum breakout, and risk hedging.
RxSight, Inc. To Report Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026
RxSight, Inc. announced it will release its fourth quarter and full year 2025 financial results after the market closes on Wednesday, February 25, 2026. Management will host a conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss these results, which will also be webcast live on the company's investor relations website. The company specializes in an adjustable intraocular lens system for cataract surgery.
RxSight, Inc. To Report Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026
RxSight, Inc. announced that it will report its financial results for the fourth quarter and full year 2025 after market close on Wednesday, February 25, 2026. The company will host a conference call and webcast to discuss these results at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. RxSight specializes in ophthalmic medical devices, specifically the Light Adjustable Lens system for customized vision after cataract surgery.
RxSight, Inc. (RXST) Initiated at Market Perform as Firm Seeks Sales Reacceleration
William Blair initiated coverage of RxSight, Inc. (RXST) with a "Market Perform" rating due to stalled sales growth expected in 2025 following strong early adoption. The firm awaits evidence of sustained commercial reacceleration, despite the stock's discounted trading. RxSight narrowed its full-year revenue guidance and is focusing on international expansion, but the article suggests greater upside potential in certain AI stocks.
New York State Common Retirement Fund Sells 341,274 Shares of RxSight, Inc. $RXST
The New York State Common Retirement Fund significantly reduced its stake in RxSight, Inc. (NASDAQ:RXST) by selling 341,274 shares, decreasing its total holding to 125,649 shares. This 73.1% reduction values its remaining stake at approximately $1.13 million. Despite overall institutional ownership at 78.78%, RxSight currently holds a consensus "Reduce" rating from Wall Street analysts with an average target price of $9.78.
10 Best Long Term Healthcare Stocks to Buy
This article identifies RxSight, Inc. (NASDAQ:RXST) as one of the 10 best long-term healthcare stocks to buy. It details William Blair's "Market Perform" rating on the company, citing stalled sales growth needing reacceleration, despite the stock trading at a discount. The article also highlights RxSight's narrowed full-year revenue guidance and its progress in international expansion, particularly in Asia and Europe.
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against RxSight, Inc. (RXST) And Encourages Investors to Reach Out
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against RxSight, Inc. (NASDAQ:RXST) on behalf of investors who purchased securities before November 7, 2024, and still hold them. The investigation focuses on whether RxSight and its officers engaged in corporate wrongdoing. The law firm encourages affected investors to contact them to assist with the investigation, noting that they represent investors on a contingency fee basis.
RxSight announces executive leadership reorganization and new appointments
RxSight has announced a significant executive leadership reorganization, including several new appointments. The changes are intended to streamline operations and enhance strategic execution within the company.
The Technical Signals Behind (RXST) That Institutions Follow
The article analyzes Rxsight Inc. (NASDAQ: RXST) using AI models to identify technical signals and institutional trading strategies. It highlights a weak sentiment across all time horizons supporting a short bias, an exceptional risk-reward setup targeting an 86.5% gain, and specific entry, target, and stop-loss levels for position, momentum, and risk-hedging strategies. The analysis also provides multi-timeframe signal analysis indicating weak signals across near-term, mid-term, and long-term horizons, along with corresponding support and resistance levels.
Brown Capital Management LLC Trims Stock Position in RxSight, Inc. $RXST
Brown Capital Management LLC reduced its stake in RxSight, Inc. (NASDAQ:RXST) by 31.1% in the third quarter of 2025, now holding shares worth approximately $6.93 million. This comes as analysts generally have a "Reduce" consensus rating for RxSight, despite the company recently beating quarterly EPS and revenue estimates, though revenue still saw a significant year-over-year decline. The medical technology company, specializing in Light Adjustable Lenses for cataract surgery, remains unprofitable with a negative net margin and return on equity.
Bronstein, Gewirtz & Grossman, LLC Is Investigating RxSight, Inc. (RXST) And Encourages Stockholders to Connect
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of RxSight, Inc. (RXST) investors who purchased securities before November 7, 2024, and continue to hold them. The investigation concerns whether RxSight and its officers engaged in corporate wrongdoing. The firm encourages affected stockholders to connect with them for more information and to assist in the investigation.
RxSight stock initiated with Market Perform rating by William Blair
William Blair initiated coverage on RxSight Inc. (NASDAQ:RXST) with a Market Perform rating, despite the stock appearing undervalued by InvestingPro metrics. The firm acknowledged RxSight's past growth but raised concerns about increased competition, post-operative support for surgeons, and insufficient focus on new customer integration, leading them to seek evidence of sustainable performance turnaround before a more positive outlook. Other analysts like Jefferies, Stifel, and UBS also maintained cautious ratings, although RxSight did report better-than-expected preliminary Q4 2025 revenue.
Needham Lowers Price Target on RxSight to $13 From $14, Keeps Buy Rating
Needham has adjusted its price target for RxSight (NASDAQ: RXST) to $13, down from $14, while maintaining a Buy rating on the stock. This update comes as RxSight's stock showed a 5-day change of -2.36% and a year-to-date change of -16.70%, with a current price of $8.700. The company, a commercial-stage medical technology firm, focuses on improving vision after cataract surgery with its RxSight Light Adjustable Lens system.
RxSight stock initiated with Market Perform rating by William Blair
William Blair initiated coverage on RxSight Inc. (NASDAQ:RXST) with a Market Perform rating, despite the stock appearing undervalued by InvestingPro metrics and experiencing a significant decline over the past year. The firm noted that RxSight achieved robust growth from 2021-2024, but sales stalled in 2025 due to competitive headwinds and challenges in customer support. While RxSight trades at a discount to peers, William Blair seeks evidence of sustainable performance turnaround before a more positive outlook.
William Blair Starts RxSight Inc. (RXST) at Market Perform
William Blair analyst Steven Lichtman has initiated coverage on RxSight Inc. (NASDAQ: RXST) with a Market Perform rating. The full analyst report, which begins with the thesis for this rating, is available to StreetInsider.com Premium subscribers. This article serves as an announcement of the new coverage rating.
William Blair Initiates Coverage on RxSight With Market Perform
William Blair has initiated coverage on RxSight, Inc. (RXST) with a Market Perform rating. This news follows a recent report by Needham, which lowered its price target for RxSight to $13 from $14 but maintained a Buy rating, indicating differing analyst perspectives on the company's immediate future. RxSight is a medical technology company focused on improving vision after cataract surgery with its Light Adjustable Lens system.
RxSight, Inc. (NASDAQ:RXST) Given Consensus Rating of "Reduce" by Analysts
RxSight, Inc. (NASDAQ:RXST) has received a consensus "Reduce" rating from analysts, with an average 1-year price target of $9.78. Despite beating EPS and revenue estimates in its last quarterly report, the company remains unprofitable. Institutional investors hold a significant portion of the stock, with notable increases in holdings by firms like Goldman Sachs.
Baillie Gifford & Co. Raises Stock Holdings in RxSight, Inc. $RXST
Baillie Gifford & Co. increased its stake in RxSight, Inc. by 46.4% in the third quarter of 2025, acquiring an additional 217,371 shares to own a total of 686,316 shares worth approximately $6.17 million. Other institutional investors also raised their positions, leading to institutional ownership of about 78.78%. Despite beating EPS and revenue estimates in its latest quarterly report, RxSight's revenue was down 31.4% year-over-year, and the company remains unprofitable with a MarketBeat consensus rating of "Reduce" and a price target of $9.78.
Precision Trading with Rxsight Inc. (RXST) Risk Zones
This article provides a detailed analysis of Rxsight Inc. (RXST) with a focus on risk zones and trading strategies developed by AI models. It highlights a near-term neutral sentiment amidst mid and long-term weakness, identifying resistance and potential support levels. The analysis offers specific entry and exit points for various trading strategies, including position, momentum breakout, and risk hedging, along with multi-timeframe signal analysis and risk-reward ratios.
RxSight (NASDAQ:RXST) Trading Down 0.9% - Time to Sell?
RxSight (NASDAQ:RXST) recently saw its stock trade down 0.9%, with increased trading volume. Analyst sentiment is generally weak, with an average "Reduce" rating and a target price near the current share price. While the company beat quarterly EPS and revenue estimates, revenue was down significantly year-over-year, and it remains unprofitable.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of RxSight, Inc. - RXST
Pomerantz LLP has launched an investigation into RxSight, Inc. (NASDAQ: RXST) following allegations of potential securities fraud or unlawful business practices. This probe follows a significant drop in RxSight's stock price after the announcement of its Chief Financial Officer's departure, raising concerns about ongoing commercial challenges and management instability. Investors who have suffered losses are encouraged to contact Pomerantz LLP to explore potential class action involvement.
Bronstein, Gewirtz & Grossman, LLC Is Investigating RxSight, Inc. (RXST) And Encourages Investors to Connect
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of RxSight, Inc. (NASDAQ: RXST). The firm encourages investors who bought RxSight securities before November 7, 2024, and still hold them, to contact them to assist in the investigation into possible corporate wrongdoing by RxSight and its officers/directors. Investors can find more information and connect with the firm at bgandg.com/RXST to participate in the no-cost investigation.
Bronstein, Gewirtz & Grossman, LLC Encourages RxSight, Inc. (RXST) Stockholders to Inquire about Securities Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of RxSight, Inc. (NASDAQ:RXST) securities. The investigation focuses on whether RxSight and its officers engaged in corporate wrongdoing. The firm encourages stockholders who purchased shares before November 7, 2024, and still hold them, to contact them for more information and to assist in the investigation.
RxSight stock price target raised to $11.50 from $11.00 at Jefferies
Jefferies has increased its price target for RxSight Inc. (NASDAQ:RXST) to $11.50 from $11.00, maintaining a Hold rating. This adjustment follows RxSight's preliminary Q4 2025 revenue of $32.6 million, which exceeded consensus estimates, despite a 19% year-over-year decline. The company also announced a new CFO and is expected to provide full 2026 guidance in February.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of RxSight, Inc. - RXST
Pomerantz LLP is investigating RxSight, Inc. (RXST) on behalf of investors regarding potential securities fraud or unlawful business practices. This investigation follows the surprising departure of RxSight's CFO, Shelley Thunen, announced on December 22, 2025, which led to a nearly 10% drop in stock price. The firm is encouraging affected investors to contact them to join a potential class action lawsuit.
RxSight stock price target raised to $11.50 from $11.00 at Jefferies
Jefferies raised its price target for RxSight Inc. (NASDAQ:RXST) to $11.50 from $11.00, reiterating a Hold rating despite the stock's significant decline over the past year. The adjustment follows RxSight reporting preliminary fourth-quarter 2025 revenue of $32.6 million, surpassing consensus estimates, and maintaining strong financial health with a high current ratio and more cash than debt. The company expects to provide full 2026 guidance in February.
RxSight stock price target raised to $11.50 from $11.00 at Jefferies
Jefferies has increased its price target for RxSight Inc. (NASDAQ:RXST) to $11.50 from $11.00, maintaining a Hold rating. This adjustment follows RxSight's preliminary Q4 2025 revenue report of $32.6 million, which surpassed consensus estimates despite a year-over-year decline. The company also announced a new CFO and continues to exhibit strong financial health, with full 2026 guidance expected in February.
RxSight stock price target raised to $11.50 from $11.00 at Jefferies
Jefferies has raised its price target on RxSight Inc. (NASDAQ:RXST) to $11.50 from $11.00, maintaining a Hold rating, following RxSight's preliminary fourth-quarter 2025 revenue report which exceeded consensus estimates. Despite a decline in Light Delivery Device and Light Adjustable Lens sales year-over-year, the company shows strong financial health and expects to provide full 2026 guidance in February. Other analysts like Stifel and UBS have also updated their outlooks on RxSight, with varying price targets and concerns about competition.
RxSight Inc. (RXST) PT Raised to $11.50 at Jefferies
Jefferies analyst Young Li has raised the price target for RxSight Inc. (NASDAQ: RXST) to $11.50 from $11.00. The analyst opted to maintain a prior rating on the stock. This article, posted on January 13, 2026, requires a premium subscription to view the full details.
RxSight Shows Growth in Preliminary Q4 and 2025 Results; Names Mark Wilterding as CFO
RxSight, Inc. announced preliminary unaudited financial results for Q4 and full-year 2025, projecting revenues of $32.6 million and $134.5 million respectively, driven by increased sales of Light Adjustable Lenses (LALs) and Light Delivery Devices (LDDs). The company also announced the appointment of Mark Wilterding, formerly of Edwards Lifesciences, as its new Chief Financial Officer. Despite market headwinds, RxSight reported significant progress and strengthened its position for long-term growth.
RxSight Announces New CFO and Strong Preliminary Results
RxSight reported preliminary unaudited Q4 2025 revenue of approximately $32.6 million and full-year revenue of roughly $134.5 million, surpassing previous guidance. The company also announced the appointment of Mark Wilterding as its new Chief Financial Officer, effective January 11, 2026. Despite strong operational results and cash reserves, Spark, TipRanks' AI Analyst, rates RXST as Neutral due to financial challenges including negative profitability and P/E ratio, despite some positive technical indicators.
Stifel reiterates Hold rating on RxSight stock amid competition concerns
Stifel maintained a Hold rating and $10.00 price target on RxSight Inc. (NASDAQ:RXST) due to concerns about increased competition in the U.S. premium intraocular lens (IOL) market which could impact sales of RxSight’s Light Adjustable Lens (LAL). Despite these concerns, InvestingPro data suggests the stock is undervalued, and recent Q4 2025 revenue estimates and Q3 results exceeded expectations, leading other firms like Needham to raise price targets. The company is facing strategic transitions, including a CFO change, and upcoming investor discussions will focus on sustained growth.
Planet Labs PBC, Day One Biopharmaceuticals, Rxsight, SunOpta And Other Big Stocks Moving Higher On Monday
Several companies, including Planet Labs PBC, Day One Biopharmaceuticals, Rxsight, and SunOpta, saw significant stock gains on Monday. These increases were driven by various factors such as new agreements, strong preliminary revenue figures, raised guidance, and strategic announcements. The market also observed a general trend of precious metals trading higher due to concerns about Federal Reserve independence.
Benign Growth For RxSight, Inc. (NASDAQ:RXST) Underpins Stock's 30% Plummet
RxSight, Inc. (NASDAQ:RXST) shares recently dropped 30%, adding to a 71% loss over the past year. Despite a seemingly attractive price-to-sales (P/S) ratio of 2.6x compared to the industry average, analysts forecast a modest 3.4% annual revenue growth for RxSight over the next three years, significantly trailing the industry's projected 111% growth. This underwhelming outlook for future revenue is a key factor contributing to the stock's low P/S ratio and the negative investor sentiment.
RxSight guides FY revenue above previous estimates, names new CFO
RxSight has updated its financial guidance for fiscal year 2024, raising its revenue expectations after a strong preliminary report for the fourth quarter of 2023. The company now projects FY 2024 revenue to be between $96 million and $100 million. Additionally, RxSight announced the appointment of Shelley B. Thunen as its new Chief Financial Officer, effective January 22.
RXST - Rxsight, Inc. Latest Stock News & Market Updates
This page serves as a dedicated news hub for RxSight, Inc. (RXST), offering investors and traders updates on the company's stock, clinical advancements, and strategic developments in light adjustable lens technology. Key coverage includes quarterly earnings, FDA clearances, and partnership announcements, with recent news detailing preliminary Q4 and full-year 2025 financial results, a new CFO appointment, and presentations at upcoming healthcare conferences. RxSight focuses on redefining cataract care through personalized ophthalmic solutions.
RxSight Sees Q4 Revenue Above View; Names Mark Wilterding CFO
RxSight Inc. (RXST) announced that its Q4 2025 revenue is expected to be approximately $32.6 million, surpassing analysts' expectations of $27.53 million. The company's preliminary unaudited 2025 fiscal year revenue is projected at $134.5 million, exceeding earlier guidance. Additionally, RxSight appointed Mark Wilterding as its new Chief Financial Officer, effective January 11, 2026, bringing over 25 years of financial leadership experience to the role.
RxSight reports Q4 revenue of $32.6 million, exceeds 2025 guidance By Investing.com
RxSight, Inc. announced preliminary unaudited Q4 2025 revenue of $32.6 million, surpassing its full-year guidance with total 2025 revenue of $134.5 million. The company's strong financial position is highlighted by its cash reserves and a current ratio of 12.74, and it also appointed Mark Wilterding as its new CFO. RxSight credits its success to increased LAL sales and an expanded installed base of Light Delivery Devices, while expecting to release full audited results and 2026 guidance in February.
RxSight says Mark Wilterding appointed as CFO effective Jan 11, 2026
RxSight, Inc. announced that Mark Wilterding has been appointed as the company's new Chief Financial Officer, with his tenure effective January 11, 2026. This appointment comes after the previous CFO, Shelley Thunen, announced her decision to step down in December. The news was published on January 11, 2026, at 09:37 am EST.
RxSight Says Mark Wilterding Appointed As CFO Effective Jan 11, 2026
RxSight announced the appointment of Mark Wilterding as its new Chief Financial Officer. His appointment is effective starting January 11, 2026. This news was reported by Reuters.
Adjustable cataract lens maker adds more devices and a new finance chief
RxSight, an ophthalmic medical device company, announced preliminary unaudited financial results for Q4 and full-year 2025, exceeding previous revenue guidance with $134.5 million for the full year. The company also reported increased sales of its Light Adjustable Lenses (LAL) and Light Delivery Devices (LDD), expanding its installed base. Additionally, RxSight announced the appointment of Mark Wilterding as its new Chief Financial Officer, effective January 11, 2026.
RxSight, Inc. Announces Preliminary Q4 and 2025 Financial Results; New Chief Financial Officer
RxSight, Inc. announced preliminary unaudited financial and operational results for Q4 and full-year 2025, with revenues exceeding guidance. The company reported strong growth in Light Adjustable Lens (LAL) sales and an expanded installed base of Light Delivery Devices (LDDs). Additionally, RxSight announced the appointment of Mark Wilterding as its new Chief Financial Officer, effective January 11, 2026.
RxSight reports Q4 revenue of $32.6 million, exceeds 2025 guidance
RxSight, Inc. reported preliminary unaudited fourth-quarter 2025 revenue of $32.6 million, surpassing its full-year 2025 guidance with an estimated $134.5 million in revenue. The company also announced the appointment of Mark Wilterding as its new Chief Financial Officer. Despite headwinds, RxSight increased its Light Adjustable Lens procedure volume by 10% in Q4 and holds a strong financial position with significant cash reserves.
RxSight, Inc. Announces Preliminary Q4 and 2025 Financial Results; New Chief Financial Officer
RxSight, Inc. announced strong preliminary unaudited financial results for Q4 and full-year 2025, with revenues of $32.6 million and $134.5 million respectively, exceeding previous guidance. The company also announced the appointment of Mark Wilterding as its new Chief Financial Officer, succeeding Shelley Thunen. RxSight highlighted its continued growth in Light Adjustable Lens (LAL) sales and an expanded installed base of Light Delivery Devices (LDDs), positioning it for long-term growth in the premium intraocular lens market.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of RxSight, Inc. ...
Pomerantz LLP is investigating potential claims on behalf of investors of RxSight, Inc. (NASDAQ: RXST) concerning possible securities fraud or unlawful business practices by the company's officers and/or directors. This investigation follows a December 22, 2025, announcement that RxSight's Chief Financial Officer would be leaving, an event that led to a significant drop in RxSight's stock price. Interested investors are encouraged to contact Danielle Peyton at Pomerantz LLP for more information.
Bronstein, Gewirtz & Grossman, LLC Encourages RxSight, Inc. (RXST) Investors to Inquire about Securities Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of RxSight, Inc. (NASDAQ:RXST) securities. Investors who bought shares before November 7, 2024, and still hold them, are encouraged to assist the investigation into potential corporate wrongdoing by RxSight and its officers/directors. The firm operates on a contingency fee basis, only seeking reimbursement if successful in recovering funds for investors.
RxSight, Inc. to Present at the J.P. Morgan Healthcare Conference
RxSight, Inc., an ophthalmic medical device company, announced its participation in the upcoming J.P. Morgan Healthcare Conference. Management is scheduled to present on Tuesday, January 13, 2026, at 3:45 p.m. Pacific Time. A live and archived webcast will be available for interested parties.
